At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed Apr 14, 2026 at 22:38 ET
Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, raising approximately $403.0 million in gross proceeds, with an additional $60.5 million option for underwriters to purchase more shares. The offering is expected to close on April 16, 2026, subject to customary conditions.
- Spyre Therapeutics is offering 6,500,000 shares of common stock at $62.00 per share.
- Gross proceeds are expected to be approximately $403.0 million, before underwriting discounts and expenses.
- Underwriters have a 30-day option to purchase up to an additional $60.5 million worth of shares.
- The offering is expected to close on or about April 16, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access